wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
   Journals
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Archive
     Editorial staff
     Editorial board
     For authors
     Subscription
Otorhinolaryngology
Allergology Review



 Search in articles:
  Authority of Polish Society of Allergology




vol 20. no 4. December 2015  
 TABLE OF CONTENT

 Review articles
Omalizumab in the treatment of urticaria
Joanna Dawicka, Aleksandra Wilkowska, Roman Nowicki

Urticaria is one of the most common dermatological diseases, characterised
by the sudden appearance of wheels, angioedema, or both. Chronic
urticaria, the symptoms of which last for at least 6 weeks, is divided into
chronic spontaneous urticaria (CSU) and inducible urticaria. CSU significantly
impairs the quality of life. According to the latest guidelines the
first line treatment of urticaria are the second-generation H1-antihistamines.
If the therapy is ineffective, the doses should be increased up
to four times the licensed dose (the second line treatment). The recommended
third-line treatment includes add-on therapy with omalizumab,
cyclosporine A or montelukast. Omalizumab is a recombinant humanized
monoclonal antibody that binds free IgE. In 2014 omalizumab, so far
applied in the treatment of asthma, was registered for the treatment of
CSU. Well-controlled clinical trials proved that omalizumab is well-tolerated
and highly effective in reducing the itching severity as well as the number
of wheals. Omalizumab is a safe and effective drug in the treatment
of patients with CSU who remain symptomatic despite the high doses of
second-generation antihistamines.

keywords: pokrzywka przewlekła spontaniczna, anty-IgE, omalizumab, przeciwciała monoklonalne, chronic spontaneous urticaria, anti-IgE, omalizumab, monoclonal antibody

pages: from 218 to 222



estimated time of download (103 kB)
broadband speed:561282565121024[kbps]
time:227432[sec]


You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.


Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.